Related Experiment Video
Updated: Feb 28, 2026

Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse
Published on: October 6, 2023
Paroxysmal dyskinesia associated with hyperthyroidism in 7 cats: a novel manifestation of a metabolic encephalopathy
Javier Espinosa1, Irene Espadas2, Athina Karpozilou3
1Neurology and Neurosurgery Service, IVC Evidensia, Pride Veterinary Referrals, Derby, DE24 8HX, United Kingdom.
Background:
Paroxysmal dyskinesia associated with hyperthyroidism (HT) is a well-described disorder in humans and has not been previously reported in cats.
Hypothesis/Objectives:
Paroxysmal dyskinesia might develop as a consequence of HT in cats, with improvement or cessation of the episodes once normal thyroid function is restored.
Animals:
Seven client-owned cats.
Methods:
Multicenter retrospective observational study comprising cats with clinical signs consistent with the clinical phenotype of paroxysmal dyskinesia based on video recordings, and a concurrent diagnosis of HT. Follow-up information was obtained by contacting referring veterinarians and owners.
Results:
Seven cats were included. No signs of neurological disease were observed between the episodes except for plantigradism in one cat. Brain MRI studies were performed in 2 cats, revealing no intracranial abnormalities. In 1 cat, a 2-h video-assisted wireless electroencephalography confirmed the absence of epileptic activity. Clinical signs associated with HT were noted in all but 1 cat. After treatment for HT, complete remission of paroxysmal dyskinesia episodes was achieved in all cases, with euthyroid state confirmed in 6 cats.
Conclusions And Clinical Importance:
HT should be considered a differential diagnosis in cats with paroxysmal dyskinesia, even in the absence of other suggestive signs. Similar to the analogous disorder in humans, the prognosis appears excellent once appropriate treatment for HT is initiated.
More Related Videos
05:51Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
Related Concept Videos
Toxidromes: Clinical Features
Dysrhythmias III: Characteristics of Dysrhythmias
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists